Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $43.6 million.

  • ImmunityBio's Accumulated Expenses rose 1.38% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 1.38%. This contributed to the annual value of $40.6 million for FY2024, which is 498.27% down from last year.
  • Latest data reveals that ImmunityBio reported Accumulated Expenses of $43.6 million as of Q3 2025, which was up 1.38% from $35.7 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Accumulated Expenses ranged from a high of $64.9 million in Q3 2023 and a low of $27.9 million during Q1 2025
  • Its 5-year average for Accumulated Expenses is $45.7 million, with a median of $43.6 million in 2024.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 60072.77% in 2021, then plummeted by 4329.99% in 2024.
  • ImmunityBio's Accumulated Expenses (Quarter) stood at $51.4 million in 2021, then decreased by 18.61% to $41.8 million in 2022, then rose by 2.11% to $42.7 million in 2023, then fell by 4.98% to $40.6 million in 2024, then grew by 7.45% to $43.6 million in 2025.
  • Its Accumulated Expenses was $43.6 million in Q3 2025, compared to $35.7 million in Q2 2025 and $27.9 million in Q1 2025.